According to Sina Finance, Barclays published a research report on Europe’s medical technology and services sector on November 19, naming EssilorLuxottica its top pick and favoring companies with strong competitive barriers, stable demand and clear earnings growth prospects.
Barclays said expectations for growth in EssilorLuxottica’s wearables business had been substantially lowered and were now more reasonable. It said the company’s core eyewear business has strong competitive barriers and resilient demand, and that its shares trade at a significant discount to the bank’s assessment of fair value.
Among medical-device makers, Barclays favored Philips, with its adjusted EBIT forecast 6% above market consensus. The bank said it had become more confident in management’s ability to deliver earnings growth and viewed Philips’ patient-monitoring business as differentiated. It said the sector faces potential tariff increases, rising production costs and limited pricing power, but demand is resilient and reimbursement-policy and regulatory risks are relatively low.
Barclays preferred Fresenius Group over its former controlled subsidiary Fresenius Medical Care, forecasting stable mid-single-digit growth. It said expansion at Fresenius Kabi could push the group’s medium-term margin above its target. A recent strategic biosimilar deal could generate an additional €2.5 billion in revenue, a long-term growth opportunity Barclays said was not fully reflected in the valuation. Fresenius traded at about 14 times estimated 2027 earnings, compared with 22 times for Sandoz; Barclays expected the valuation gap to narrow gradually.
